Trump's administration eases federal stance on medical marijuana

In a notable shift, the Trump administration has moved to reclassify state-licensed medical marijuana as a less dangerous drug under federal regulations. The Justice Department's updated stance, announced Thursday, removes some long-standing barriers that have blocked scientific research and kept cannabis businesses from accessing basic financial benefits like federal tax deductions.

The change means that medical marijuana products produced and distributed under strict state licensing rules will no longer be treated as strictly as harder narcotics under federal scheduling. While recreational cannabis remains fully illegal at the national level, the reclassification opens the door for universities, pharmaceutical researchers, and doctors to study the drug more freely. It also allows compliant medical dispensaries to claim tax breaks that have been off-limits for decades, simply because they dealt in a federally banned substance.

The move builds on an executive order President Trump signed in 2025, which directed federal agencies to review cannabis policy in light of widespread state legalization. At the time, the order was seen as a cautious signal rather than a full endorsement. Now, with the reclassification in place, it's clear the administration is willing to act-albeit within narrow boundaries. Officials emphasized that the change applies only to medical use in states where it's already legal and regulated.

Reaction has been mixed. Public health advocates and patient groups welcomed the decision as a long-overdue recognition of medical reality. For years, doctors have prescribed cannabis for chronic pain, epilepsy, and cancer-related symptoms, even as federal rules treated it as highly dangerous. "This is about aligning policy with science," said one researcher at a major medical university, who spoke on background.

Still, many reform advocates say the step doesn't go far enough. Thousands of people remain in prison for nonviolent cannabis offenses, and recreational users-and the businesses serving them-still operate in legal gray zones. Some Democratic lawmakers called the move "symbolic" without broader decriminalization or expungement measures. Meanwhile, conservative critics worry the change undermines drug enforcement efforts and could encourage broader use.

Politically, the shift reflects a quiet evolution in how even Republican-led administrations approach drug policy. With polls showing strong public support for medical marijuana across party lines, the reclassification may be as much about pragmatism as principle. It also comes amid internal administration turbulence, including recent cabinet shake-ups, suggesting Trump may be focusing on achievable wins as his second term unfolds.

For now, the reclassification won't change daily life for most Americans. But for researchers, patients, and business owners in legal states, it removes real obstacles that have slowed progress for years. Whether this leads to broader reform-or remains a limited exception-will likely depend on what Congress and future administrations choose to do next.